Last reviewed · How we verify
ABT-712
ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation.
ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation. Used for Lung cancer with FGFR1 alterations, Other solid tumors with FGFR1 dependency.
At a glance
| Generic name | ABT-712 |
|---|---|
| Also known as | Hydrocodone and acetaminophen extended-release, Hydrocodone bitartrate and acetaminophen extended-release, Hydrocodone/acetaminophen extended-release |
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | FGFR1 inhibitor |
| Target | FGFR1 (Fibroblast Growth Factor Receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ABT-712 targets FGFR1, a receptor tyrosine kinase involved in cell proliferation and survival in certain cancers. By inhibiting FGFR1 signaling, the drug aims to suppress tumor growth in malignancies driven by FGFR1 alterations or overexpression. This mechanism is particularly relevant in cancers with FGFR1 amplification or activating mutations.
Approved indications
- Lung cancer with FGFR1 alterations
- Other solid tumors with FGFR1 dependency
Common side effects
- Hyperphosphatemia
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Acute Pain Study Following Bunionectomy (PHASE2)
- Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy (PHASE2)
- Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction (PHASE2)
- Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) (PHASE3)
- Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) (PHASE3)
- Phase 2 Chronic Low Back Pain Study (PHASE2)
- A Study of Pain Relief in Osteoarthritis (PHASE3)
- A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-712 CI brief — competitive landscape report
- ABT-712 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI